These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 11156256)

  • 1. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
    Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
    Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy and rituximab.
    Czuczman MS
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S15-9. PubMed ID: 11508932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
    Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
    Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
    Itoh T; Sakata Y; Suzuki H; Sugimoto N; Sohma N; Kishibe T; Higuchi S; Seino Y
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):241-4. PubMed ID: 1371049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.